CyberKnife Eyes Volumetric Imaging With Samsung

Accuray and Samsung NeuroLogica are exploring how volumetric imaging could be brought closer to treatment delivery on the CyberKnife platform. The collaboration combines Accuray’s experience in robotic radiosurgery and motion management with Samsung NeuroLogica’s work in mobile computed tomography. It is an interesting technical direction, but the distinction matters: this is a phased development program, not the launch of a purchasable CyberKnife imaging upgrade.

What the collaboration is trying to add

CyberKnife is designed for highly precise, non-coplanar radiation delivery, with the robotic system able to approach a target from multiple angles. Its real-time motion management is particularly relevant when anatomy can move during treatment. The proposed volumetric imaging work would investigate whether clinicians can gain a broader, three-dimensional view of the target and surrounding anatomy in the treatment environment.

That additional context could matter because a tumor does not exist in isolation. Nearby organs and other healthy structures may shift between treatment sessions, while targets in areas such as the lung or abdomen can also move. Accuray says clinicians have identified imaging that supports treatment efficiency and informed decision-making as a priority.

Why mobile CT expertise is relevant

Samsung NeuroLogica develops mobile CT systems intended to bring imaging to the patient. Pairing that experience with CyberKnife could reduce the conceptual gap between acquiring a detailed anatomical data set and making a treatment decision. The companies have not disclosed a final hardware configuration or explained exactly how a CT system would connect with the treatment platform, so it is too early to judge installation requirements or workflow speed.

The practical goal is clearer than the implementation: provide more anatomical information in the treatment room. If successfully developed, such a workflow could help a clinical team assess the relationship between the treatment target and nearby healthy organs without treating motion tracking and volumetric visualization as unrelated tools.

Potential role in adaptive radiotherapy

The longer-term opportunity is adaptive radiotherapy, in which a treatment plan can be adjusted to reflect the patient’s anatomy on a particular day. Clinicians quoted in the announcement highlighted potential relevance across thoracic, abdominal, and pelvic cancers, including lung, pancreatic, and prostate cases. However, these comments describe clinical possibilities rather than validated capabilities of a released product.

The Royal Marsden NHS Foundation Trust is identified as the first center participating in the collaboration. Its involvement should give the companies access to treatment-room feedback while they investigate how volumetric data might complement CyberKnife’s existing non-coplanar delivery and real-time motion management.

Important limitations at this stage

Several details remain unknown, including image-acquisition time, radiation dose from additional imaging, reconstruction performance, integration with planning software, room-layout requirements, and compatibility with installed CyberKnife systems. There are also no published specifications, clinical performance results, price, or availability date in the announcement.

Development will proceed in phases as the companies assess technical, clinical, and commercial options. Any future implementation would also need to meet the regulatory standards applied to radiation-oncology equipment. For now, the collaboration is best viewed as a signal of where image-guided robotic radiosurgery may be heading, while Accuray has explicitly confirmed that no commercial product offering has been announced.